SRXH
SRx Health Solutions Inc.
Drug Manufacturers - General
Market Cap$1M
5Y Perf.-94.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SRXH vs PHVS
Revenue, margins, valuation, and 5-year total return — side by side.
PHVS
Pharvaris N.V.
Biotechnology
Market Cap$1.96B
5Y Perf.+62.9%
SRXH vs PHVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SRXH | PHVS |
|---|---|---|
| Industry | Drug Manufacturers - General | Biotechnology |
| Market Cap | $1M | $1.96B |
| Revenue (TTM) | $119M | $0.00 |
| Net Income (TTM) | $-11M | $-166M |
| Gross Margin | 19.9% | — |
| Operating Margin | -4.9% | — |
| Total Debt | $39M | $861K |
| Cash & Equiv. | $2M | $281M |
SRXH vs PHVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SRXH
PHVS
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| SRx Health Solution… (SRXH) | 100 | 5.8 | -94.2% |
| Pharvaris N.V. (PHVS) | 100 | 162.9 | +62.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SRXH vs PHVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SRXH and PHVS are tied at the top with 2 categories each — the right choice depends on your priorities. Pharvaris N.V. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SRXH
SRx Health Solutions Inc.
The Growth Play
SRXH has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 28.4%, EPS growth 74.1%
- 28.4% revenue growth vs PHVS's -23.2%
- -22.4% ROA vs PHVS's -49.0%
Best for: growth exposure
PHVS
Pharvaris N.V.
The Long-Run Compounder
PHVS is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 3.8% 10Y total return vs SRXH's -94.6%
- Lower volatility, beta 1.02, Low D/E 0.3%, current ratio 12.60x
- Beta 1.02, current ratio 12.60x
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SRXH | 28.4% revenue growth vs PHVS's -23.2% |
| Quality / Margins | PHVS | 1.9% margin vs SRXH's -9.4% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PHVS | +78.9% vs SRXH's -86.7% |
| Efficiency (ROA) | SRXH | -22.4% ROA vs PHVS's -49.0% |
SRXH vs PHVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPHVSLAGGINGSRXH
SRXHSRx Health Solutions …
0leads
PHVSPharvaris N.V.
3leads
6 Total Categories
CATEGORYLEADERvs SRXHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
PHVS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PHVS3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
PHVS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
SRXH and PHVS operate at a comparable scale, with $119M and $0 in trailing revenue.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. |
|---|---|---|
| RevenueTrailing 12 months | $119M | $0 |
| EBITDAEarnings before interest/tax | — | -$86M |
| Net IncomeAfter-tax profit | — | -$166M |
| Free Cash FlowCash after capex | — | -$134M |
| Gross MarginGross profit ÷ Revenue | +19.9% | — |
| Operating MarginEBIT ÷ Revenue | -4.9% | — |
| Net MarginNet income ÷ Revenue | -9.4% | — |
| FCF MarginFCF ÷ Revenue | +1.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +22.1% |
Insufficient data to determine a leader in this category.
Valuation Metrics
PHVS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. |
|---|---|---|
| Market CapShares × price | $1M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $29M | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | -10.35x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.02x | — |
| Price / BookPrice ÷ Book value/share | — | 5.18x |
| Price / FCFMarket cap ÷ FCF | 1.21x | — |
PHVS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
PHVS leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), SRXH scores 3/9 vs PHVS's 1/9, reflecting mixed financial health.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. |
|---|---|---|
| ROE (TTM)Return on equity | — | -53.2% |
| ROA (TTM)Return on assets | -22.4% | -49.0% |
| ROICReturn on invested capital | -18.1% | — |
| ROCEReturn on capital employed | -98.8% | -44.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | $37M | -$280M |
| Cash & Equiv.Liquid assets | $2M | $281M |
| Total DebtShort + long-term debt | $39M | $861,470 |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | — |
PHVS leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
PHVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PHVS five years ago would be worth $12,371 today (with dividends reinvested), compared to $541 for SRXH. Over the past 12 months, PHVS leads with a +78.9% total return vs SRXH's -86.7%. The 3-year compound annual growth rate (CAGR) favors PHVS at 48.1% vs SRXH's -62.2% — a key indicator of consistent wealth creation.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. |
|---|---|---|
| YTD ReturnYear-to-date | -52.5% | +13.7% |
| 1-Year ReturnPast 12 months | -86.7% | +78.9% |
| 3-Year ReturnCumulative with dividends | -94.6% | +225.2% |
| 5-Year ReturnCumulative with dividends | -94.6% | +23.7% |
| 10-Year ReturnCumulative with dividends | -94.6% | +3.8% |
| CAGR (3Y)Annualised 3-year return | -62.2% | +48.1% |
PHVS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SRXH and PHVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than PHVS's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHVS currently trades 96.8% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.32x | 1.02x |
| 52-Week HighHighest price in past year | $1.25 | $31.12 |
| 52-Week LowLowest price in past year | $0.08 | $14.59 |
| % of 52W HighCurrent price vs 52-week peak | +9.0% | +96.8% |
| RSI (14)Momentum oscillator 0–100 | 41.0 | 56.8 |
| Avg Volume (50D)Average daily shares traded | 22.0M | 223K |
Evenly matched — SRXH and PHVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $43.67 |
| # AnalystsCovering analysts | — | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PHVS leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.
Best OverallPharvaris N.V. (PHVS)Leads 3 of 6 categories
Loading custom metrics...
SRXH vs PHVS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SRXH or PHVS a better buy right now?
Analysts rate Pharvaris N.
V. (PHVS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SRXH or PHVS?
Over the past 5 years, Pharvaris N.
V. (PHVS) delivered a total return of +23. 7%, compared to -94. 6% for SRx Health Solutions Inc. (SRXH). Over 10 years, the gap is even starker: PHVS returned +3. 8% versus SRXH's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SRXH or PHVS?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc.
(SRXH) is the lower-risk stock at -0. 32β versus Pharvaris N. V. 's 1. 02β — meaning PHVS is approximately -415% more volatile than SRXH relative to the S&P 500.
04Which is growing faster — SRXH or PHVS?
On earnings-per-share growth, the picture is similar: SRx Health Solutions Inc.
grew EPS 74. 1% year-over-year, compared to 5. 7% for Pharvaris N. V.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SRXH or PHVS?
Pharvaris N.
V. (PHVS) is the more profitable company, earning 0. 0% net margin versus -9. 4% for SRx Health Solutions Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHVS leads at 0. 0% versus -4. 9% for SRXH. At the gross margin level — before operating expenses — SRXH leads at 19. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SRXH or PHVS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SRXH or PHVS better for a retirement portfolio?
For long-horizon retirement investors, SRx Health Solutions Inc.
(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). Both have compounded well over 10 years (SRXH: -94. 6%, PHVS: +3. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SRXH and PHVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SRXH is a small-cap high-growth stock; PHVS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.